Study Start Date: 05/10/2009
Study End Date: 05/10/2020

Hypertrophic Osteodystrophy (HOD): Identifying the Genes Responsible.
Hypertrophic Osteodystrophy (HOD) is a canine developmental disease that affects large breed dogs between eight weeks and eight months of age. Sick dogs exhibit swelling and pain in their legs with reluctance to stand or walk. In addition to bone pain, there are variable general signs including fever, lethargy, depression, and loss of appetite.

A diagnosis of HOD is made based on radiographic evidence of bone involvement concurrent with fever and pain, and by ruling out infectious disease. The prognosis for severe cases is poor due to relapsing episodes and the low quality of life for the affected puppies that often results in euthanasia.

HOD in the Weimaraner breed is reported in whole litters and among closely related individuals. Even though the pathogenesis of HOD is unknown, there is strong evidence suggesting an inherited component to the disease especially since HOD is more common in specific breeds.

The aim of this study is to identify the genetic basis of HOD in Weimaraners and other breeds. By investigating the chromosomal regions associated with HOD we hope to assist dog breeders to select against the disease in their breeds. Selective breeding will reduce the number of HOD affected puppies in the general population and perhaps save puppies and owners from the devastating outcome of euthanasia.

Study Design:
Prospective case-controlled study.

Inclusion Criteria:

• Radiographic images suggestive of a diagnosis of HOD
• Patient signalment
• History
• Response to treatment

Exclusion Criteria:
Diseases other than HOD.

Samples:

• Blood sample in EDTA tube is required
• Radiographs or digital high-quality reproductions of the radiographs confirming the diagnosis

External Study URL:
http://www.vetmed.ucdavis.edu/clinicaltrials/current_trials/by_species/dogs.cfm

Costs/Reimbursements:
No costs are reimbursed.

Full Disclosure Information:

• The study is funded by an intramural grant.
• The investigator does not have a conflict of interest.
• The study will be published if results are negative.
• The study will be reported on VIN
• The authors will acknowledge VIN if the study is published